RxDoctor Payments Data

Jonathan Kurohara, MD

Family Medicine · Simi Valley, CANPI 1427023407

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 101 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$402
  • GSK$194
  • Johnson & Johnson$133
  • AbbVie$128
  • Novartis$97
  • Novo Nordisk$76
  • plus $484 from 16 others

What the payments were for

  • Food & beverage$1,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,514 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$255,523
Medicare patients
474
Services billed
2,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate47$45,575
MounjaroTirzepatide41$42,957
JardianceEmpagliflozin36$37,611
EliquisApixaban42$36,394
TrulicityDulaglutide25$29,344
OzempicSemaglutide24$23,371
XareltoRivaroxaban23$18,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,312
TradjentaLinagliptin14$9,790
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$4,938
Atorvastatin Calcium576$4,576
Incruse ElliptaUmeclidinium Bromide11$3,716
Rosuvastatin Calcium163$2,984
SynthroidLevothyroxine Sodium53$2,917
Qvar RedihalerBeclomethasone Dipropionate14$2,898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$49$47,40150 claims
MerckJanuvia$57$45,57547 claims
PfizerEliquis, Paxlovid$53$37,82360 claims
Novo NordiskOzempic$76$23,37124 claims
GSKTrelegy Ellipta, Incruse Ellipta$194$19,02931 claims
Johnson & JohnsonXarelto$133$18,92823 claims
AbbVieSynthroid$128$2,91753 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$19$2,89814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Simi Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →